Targeting chemotherapy with 70-gene MammaPrint signature in patients 60 years or younger with node-negative breast cancer is likely to be cost-effective.
Kuo Bianchini Tong, MS
Advertisement
Articles by Kuo Bianchini Tong, MS
Advertisement
Latest Updated Articles
- Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer
Published: December 21st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Rural-Urban Disparities in Colorectal Cancer Screening Persist
2
Medicaid Work Rules Could Strain Hospitals: Laxmi Patel
3
Insurance Coverage Improves for Same-Sex Couples, Yet Disparities Persist
4
Identifying Barriers to Colorectal Cancer Screening for People With IDD
5
